By continuing to use this site you consent to the use of cookies on your device. Find out more about our cookie policy and the types of cookies we use by clicking here

AstraZeneca, Merck Say FDA Okays Lynparza For Metastatic Breast Cancer

LONDON (Alliance News) - AstraZeneca PLC and Merck & Co Inc, said that the US Food & Drug ...

Alliance News 14 January, 2018 | 10:32AM
Email Form

LONDON (Alliance News) - AstraZeneca PLC and Merck & Co Inc, said that the US Food & Drug Administration has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

Patients with hormone receptor positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients are selected for therapy based on an FDA-approved companion diagnostic from Myriad Genetics.

Dave Fredrickson, head of the Oncology business unit for AstraZeneca, said: "This new approval for Lynparza makes it the first and only PARP inhibitor approved in metastatic breast cancer, and the only PARP inhibitor approved beyond ovarian cancer."

This is the third indication approved for Lynparza in the US, where it has been used to treat nearly 4,000 advanced ovarian cancer patients. Lynparza has the broadest clinical development programme of any PARP inhibitor, and AstraZeneca and MSD are working together to deliver Lynparza as quickly as possible to more patients across multiple settings, including breast, ovarian, prostate and pancreatic cancers.

Under the oncology collaboration with Merck, announced in July 2017, AstraZeneca is potentially eligible for more than USD6 billion of future Sustainable and Ongoing Externalisation Revenue in the form of sales-related and approval-related payments in addition to option payments until 2019. Following this new approval for Lynparza, AstraZeneca will receive USD70 million in Sustainable and Ongoing Externalisation Revenue.

Copyright RTT News/dpa-AFX

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 5,053.00 GBX -1.50
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.